TFPI blockade: Removing coagulation’s brakes

7Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Shapiro et al report phase 2 results regarding daily concizumab prophylaxis in patients with hemophilia A or hemophilia B, thus providing proof-of-concept in preparation for the phase 3 clinical trial currently underway (NCT03741881).

References Powered by Scopus

Biology of tissue factor pathway inhibitor

239Citations
N/AReaders
Get full text

Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis

230Citations
N/AReaders
Get full text

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: A randomized first human dose trial

182Citations
N/AReaders
Get full text

Cited by Powered by Scopus

TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile

39Citations
N/AReaders
Get full text

Updates on Novel Non-Replacement Drugs for Hemophilia

23Citations
N/AReaders
Get full text

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sidonio, R. F., & Zimowski, K. L. (2019). TFPI blockade: Removing coagulation’s brakes. Blood. American Society of Hematology. https://doi.org/10.1182/blood.2019002900

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

80%

Professor / Associate Prof. 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

78%

Biochemistry, Genetics and Molecular Bi... 1

11%

Arts and Humanities 1

11%

Save time finding and organizing research with Mendeley

Sign up for free